Publications internationales
Nous mettons ici à votre disposition une sélection de publications scientifiques en rapport avec l'immunothérapie IOZK.
Vous pouvez effectuer une sélection par type de tumeur et par méthode à l'aide des filtres ou saisir des termes de recherche.
Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy
Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)
Therapeutic hyperthermia: The old, the new, and the upcoming
Dendritic cell-based immunotherapy targeting Wilms‘ tumor 1 in patients with recurrent malignant glioma
Enhancement of the Immunostimulatory Functions of Ex Vivo-Generated Dendritic Cells from Early-Stage Colon Cancer Patients by Consecutive Exposure to Low Doses of Sequential-Kinetic-Activated IL-4 and IL-12. A Preliminary Study
The therapeutic effect of death: Newcastle disease virus and its antitumor potential
Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma
Supplément du ZEIT : Leben mit Krebs avec un article sur l'IOZK et l'immunothérapie IOZK
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
Vaccination of multiple myeloma: Current strategies and future prospects
Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).
Brain Tumor Immunotherapy: What have We Learned so Far?
Étude de cas de l'IOZK sur la survie à long terme d'une patiente atteinte d'un cancer du sein
Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
Contribution du Prof. Dr Schirrmacher dans l'hebdomadaire médical viennois "Skriptum".
Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
Definitive radiotherapy with concurrent oncothermia for stage IIIB non-small-cell lung cancer: A case report
Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.
Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (INTUS trial).